In This Section

Program: Wednesday, February 26

Sunday, Feb. 23 Monday, Feb. 24 Tuesday, Feb. 25

wednesday, february 26

Wednesday, February 26

continental breakfast

7-8 a.m.

Keynote Session 4 

8-8:30 a.m.

Session Chair: Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California

  • 8:05 a.m. | Dissecting T cell recognition of human cancer
    Ton N. Schumacher, Netherlands Cancer Institute, Amsterdam, Netherlands     

education sessions 5 and 6

8:40-10 a.m.

Educational Session 5: Multi-specific Antibodies and Antibody Fusion Proteins 

Session Chair: Avery D. Posey, University of Pennsylvania, Philadelphia, Pennsylvania

  • 8:45 a.m.
    Pablo Umaña, Roche Pharma Research and Early Development, Schlieren, Switzerland
  • 9:05 a.m.
    Avery D. Posey
  • 9:25 a.m. | Engineered cytokine-antibody fusion proteins for targeted stimulation of anti-cancer immunity
    Jamie B. Spangler, Johns Hopkins Whiting School of Engineering, Baltimore, Maryland
  • 9:45 a.m. | Discussion / Q&A

Educational Session 6: Immune-related Adverse Events in IO Therapy

Session Chair: Melissa G. Lechner, UCLA David Geffen School of Medicine, Los Angeles, California

  • 8:45 a.m. | Future perspectives and targetable treatment approaches for immune-related adverse events
    Florentia Dimitriou, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 9:15 a.m.
    Melissa G. Lechner
  • 9:45 a.m. | Discussion / Q&A

break

10-10:30 a.m.

spotlight sessions 5 and 6

10:30-11:45 a.m.

Spotlight Session 5: Microbiome 

Session Chair: Thomas F. Gajewski, University of Chicago, Chicago, Illinois

  • 10:30 a.m. | Mechanisms of modulation of anti-tumor immunity by the commensal microbiota
    Thomas F. Gajewski
  • 10:55 a.m. | Understanding microbiota regulation of the tumor microenvironment and response to cancer therapy
    Romina Goldszmid, National Cancer Institute, Bethesda, Maryland
  • 11:15 a.m. | Interrogating the impact of the intestinal microbiome on CAR T cell therapy
    Melody Smith, Stanford University, Stanford, California
  • 11:35 a.m. | Discussion / Q&A

Spotlight Session 6: Oncolytic Viruses and Intratumoral Immunotherapies

Session Chair: Ignacio Melero, Clínica Universidad de Navarra, Pamplona, Spain

  • 10:35 a.m.
    John C. Bell, The Ottawa Hospital Research Institute, Ottawa, ON, Canada
  • 10:55 a.m.
    Ignacio Melero
  • 11:05 a.m. | Discussion / Q&A

lunch

11:45 a.m.-12:30 p.m.

keynote session 5

12:30-1:30 p.m.

  • 12:35 p.m. | Antibody lectin chimeras for glyco-immune checkpoint blockade
    Jessica Stark, Massachusetts Institute of Technology, Cambridge, Massachusetts
  • 1:05 p.m. | Galectins as emerging glyco-immune checkpoints: A sweet future for immunotherapy?
    Gabriel A. Rabinovich, Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina 

Major Symposium 8: New Roles of STING in Cancer Biology and Immunology 

1:30-2:30 p.m.

Session Chair: Sandra Demaria, Weill Cornell Medicine, New York, New York

  • 1:35 p.m. | STINGing tumors to improve cancer immunotherapy
    Zhijian James Chen, UT Southwestern Medical Center, Dallas, Texas
  • 1:55 p.m.
    Lingyin Li, Stanford University, Stanford, California
  • 2:15 p.m. | Discussion / Q&A

departure

2:30 p.m.